Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at 4 recent major medical meetings—the Consortium of MS Centers Annual Meeting, the Annual Joint SLEEP Meeting, the Advanced Therapeutics in Movement and Related Disorders Congress, and the American Headache Society’s Annual Scientific Meeting. Those included in this week's episode, in order of appearance, are:

Amit Bar-Or, MD, FRCPC, FAAN, FANA, the Melissa and Paul Anderson President’s Distinguished Professor at the Perelman School of Medicine of the University of Pennsylvania.

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, a professor of neurology at Barts and The London School of Medicine and Dentistry.

Dayna Johnson, PhD, MPH, MSW, MS, a sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University.

John Winkelman, MD, PhD, the chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital.

Laxman Bahroo, DO, a professor of neurology and the residency program director at MedStar Georgetown University Hospital.

Ling Wan-Albert, OTD, OTR/L, an assistant professor of occupational therapy at the New York Institute of Technology.

Sara Pavitt, MD, the chief of headache at UT Austin Dell Children’s Hospital.

Ali Ezzati, MD, the director of the Neuroinformatics Program at the University of California, Irvine.

Episode Breakdown:

1:15 – Bar-Or on the potential of BTK inhibition in multiple sclerosis at CMSC 2023

4:40 – Giovannoni on the understanding of MS as a smoldering disease at CMSC 2023

10:30 – Johnson on multilevel efforts to address modifiable factors of sleep health at SLEEP 2023

13:05 – Winkelman on moving away from dopamine agonists as first-line treatments for restless legs syndrome at SLEEP 2023

15:30 – Bahroo on the role of botulinumtoxins in Parkinson disease care at ATMRD 2023

19:00 – Wan-Albert on the impact of social isolation on cognition at ATMRD 2023

22:10 – Pavitt on the universal knowledge about pediatric headache for neurologists and nonspecialists at AHS 2023

24:05 – Ezzati on the use of machine learning models to improve treatment optimization in heterogenous migraine at AHS 2023

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of SRP-9001, or delandistrogene moxeparvovec (Elevidys; Sarepta) in Duchenne muscular dystrophy (DMD). Offering commentary is Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis. SRP-9001 is an AAV vector-based gene therapy that was approved for the treatment of ambulatory patients with DMD with a confirmed mutation in the DMD gene aged 4 to 5 years, based on data from the phase 3 EMBARK study (NCT05096221).

For more of NeurologyLive®'s coverage of SRP-9001's approval, head here: FDA Approves SRP-9001 as First Gene Therapy for Duchenne Muscular Dystrophy

Episode Breakdown:

0:30 – SRP-9001 (Elevidys; Sarepta) is approved for DMD

1:35 – Natalie Goedeker, CPNP, on the approval

3:05 – Efficacy of SRP-9001

4:00 – Goedeker on pieces of efficacy data released

4:45 – Currently available therapies for DMD

5:35 – Goedeker on role of SRP-9001 in treatment landscape

6:55 – Safety data of SRP-9001

8:00 – Goedeker on safety considerations of which prescribing clinicians should be aware

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES

1. Sarepta Therapeutics announces FDA approval of Elevidys, the first gene therapy to treat Duchenne muscular dystrophy. News release. June 22, 2023. Accessed June 22, 2023. https://www.businesswire.com/news/home/20230622454844/en/

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Ann Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, who sat down with NeurologyLive at the annual SLEEP meeting to discuss the landscape of challenges narcolepsy-related challenges that patients face, the influence of gut health on sleep apnea, how nighttime disruptions can affect treatment decisions, emerging concepts of care, and much more.

Episode Breakdown:

1:15 – Factors at play in obstructive sleep apnea

3:40 – Literature on the gut microbiome's role in sleep

5:55 – Lingering needs in narcolepsy treatment

8:30 – Neurology News Minute

12:40 – The effect of disrupted nighttime sleep

15:45 – Emerging concepts in sleep medicine

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Brandon Giglio, MD, a vascular neurologist and clinical assistant professor of neurology at NYU Grossman School of Medicine, as well as the director of Vascular Neurology at NYU Langone Hospital in Brooklyn, New York. As May is annually designated as Stroke Awareness Month in the United States, Giglio sat down with us to extend that time of awareness and share his insight into the current public understanding of stroke, how effective the care paradigm is at prevention and poststroke care, and much more.

Episode Breakdown:

1:15 – Breaking down the signs and symptoms of stroke with B.E. F.A.S.T

2:45 – The importance of stroke awareness

3:55 – Treating patients with poststroke symptoms

5:45 – Neurology News Minute

10:40 – Notable risk factors for stroke

13:15 – The critical need for novel education tools in stroke

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS and other neurological diseases. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research. 

Episode Breakdown:

1:15 – Clinical development program of CNM-Au8

3:40 – Safety findings, treatment responses of CNM-Au8

4:20 – Next steps in research 

6:25 – Neurology News Minute

8:45 – Conducting safe trials 

10:00 – Remaining unmet needs for patients with ALS

11:15 – Need for additional research

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES

1. Berry J, Maragakis N, Paganoni S, et al. Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations. Presented at: 2023 AAN Annual Meeting; April 22-27, Boston, Massachusetts.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 75th American Academy of Neurology Annual Meeting, held April 22-27, 2023, in Boston, Massachusetts. Those included in this week's episode, in order of appearance, are:

Michael H. Barnett, MBBS, PhD, FRACP, a consultant neurologist at Royal Prince Alfred Hospital (RPAH) Sydney, director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre; codirector of the MS Research Australia Brain Bank; and a senior professor at the University of Sydney.

Nancy R. Foldvary-Schaefer, DO, FAAN, the director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, and a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Sean J. Pittock, MD, the director of the Center for Multiple Sclerosis and Autoimmune Neurology and director of the Neuroimmunology Research Laboratory at Mayo Clinic.

Katherine W. Turk, MD, a neurologist at Boston VA Memory Disorders Clinic, principal investigator and codirector of the Center for Translational Cognitive Neuroscience lab (CTCN) at VA Boston; and assistant professor of neurology and coleader of the Outreach, Recruitment and Engagement core of the Alzheimer’s Disease Research Center at Boston University.

Erika U. Augustine, MD, MS, the associate chief science officer and director of the Clinical Trials Unit at the Kennedy Krieger Institute.

Jeffrey M. Statland, MD, a neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center.

Chian-Chun Chiang, MD, a stroke and migraine specialist and assistant professor of neurology at Mayo Clinic.

Episode Breakdown:

1:10 – Barnett on the topline findings for CNM-Au8 from the VISIONARY-MS clinical trial.

8:35 – Foldvary-Schaefer on the understanding of the relationship between epilepsy and sleep.

13:25 – Pittock on the latest data on ravulizumab from the CHAMPION-NMOSD trial.

19:00 – Turk on the landscape of diagnosis and treatment for mild cognitive impairment, and how to improve the process.

22:00 – Augustine on Dr. Sidney Carter and the current paradigm of care in child neurology.

27:15 – Statland on the findings for ataluren in nonsense mutation Duchenne muscular dystrophy from Study 041.

34:05 – Chiang on the takeaways from a big data analysis of 25 therapies for acute migraine management.

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES

1. Barnett MH. VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

2. Foldvary-Schaefer NR. Diagnostic Testing: Beyond the MSLT. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

3. Pittock SJ. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

4. Statland JM. Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

5. Chiang CC. Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of tofersen (Qalsody; Biogen/Ionis) in SOD1 mutation-mediated amyotrophic lateral sclerosis (ALS). Offering commentary is Angela Genge, MD, FRCPC, the director of the ALS Centre of Excellence for Research and Patient Care at McGill University, and an executive at the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). Tofersen is an antisense oligonucleotide, and its new drug application (NDA) was supported by data from a phase 1 study of healthy volunteers, a phase 1/2 dose-ascending study, the pivotal phase 3 VALOR study (NCT02623699), and its open-label extension.

For more of NeurologyLive®'s coverage of tofersen's approval, head here: FDA Approves Tofersen as First SOD1-ALS Treatment

Episode Breakdown:

0:30 – Tofersen (Qalsody; Biogen/Ionis) approved for SOD1-ALS

1:35 – Angela Genge, MD, FRCPC, on the approval

3:05 – The implications of targeting a root cause of ALS

5:00 – Data from the supporting VALOR study

5:55 – Genge on the context around the trial data

7:35 – Questions about access to tofersen amid accelerated approval

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES

1. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. News release. FDA. April 25, 2023. Accessed April 25, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

2. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099-1110. doi:10.1056/NEJMoa2204705.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum, and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York.

Episode Breakdown:

1:10 – Background on the CASA-MS study subpopulation

3:45 – Topline results of the study

6:05 – The need for further clarification in MS populations

7:10 – The utility of biomarkers such as GFAP

12:15 – Further assessment plans for the CASA-MS cohort

14:15 – Neurology News Minute

18:35 – Access to the tools to characterize progressive MS

21:30 – The potential with portable MRI and artificial intelligence

25:25 – Unmet needs in progressive MS

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE

1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430. www.abstractsonline.com/pp8/#!/10822/presentation/468

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine. 

Episode Breakdown:

1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics

3:00 – Understanding drug-to-drug interactions for PDP

5:05 – Decision making with quetiapine and negative cognitive effects

7:10 – Improved use of pimavanserin since approval

9:00 – Neurology News Minute

11:40 – Potential predictors of mortality in Parkinson disease psychosis

15:20 – Possibility of preventing PD psychosis

17:20 – Future research on identifying subgroups of responders to treatment

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Eric Zhou, PhD, assistant professor of pediatrics at Harvard Medical School. He spoke on a recently conducted study assessing the link between narcolepsy in adolescents and social relationship health. Specifically, he talked about how the sleep disorder impacts mood, physical activities, driving, and other long-term health outcomes, as well as ways we can help adolescents with narcolepsy at the earliest stages. 

Episode Breakdown:

1:20 – Identified links between narcolepsy and social relationships

3:05 – Long-term impacts of affected mood, physical activities, and driving 

4:15 – Current assessment of narcolepsy in adolescents

5:30 – Neurology News Minute

8:05 – Attempts to prevent narcolepsy at earliest stages

9:15 – Implementing programs in school to help adolescents with narcolepsy

11:20 – Future research on narcolepsy in younger populations

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.